Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology

Key Terms

non-small cell lung cancer medical

A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.

biomarker testing medical

Biomarker testing checks a sample (blood, tissue, or other body fluid) for measurable biological signs—such as specific genes, proteins, or chemicals—that indicate disease presence, progression, or likely response to a treatment. For investors, these tests matter because they can make drug development faster and more predictable, enable targeted therapies with higher success rates, and create additional markets for diagnostic services, much like a car’s dashboard lights help mechanics diagnose problems quickly.

ai-enabled clinical decision support system technical

An AI-enabled clinical decision support system is software that uses machine learning to analyze patient data and medical knowledge to help clinicians identify likely diagnoses, treatment choices, dosing or monitoring needs—like a fast, data-driven second opinion. Investors pay attention because these systems can lower costs, improve outcomes and scale across hospitals, creating recurring revenue potential, while their commercial value depends on regulatory approval, clinical proof and provider adoption.

ai-cdss technical

AI-CDSS are software systems that use artificial intelligence to analyze patient data—such as test results, medical history and imaging—and offer clinicians suggested diagnoses, treatment options or risk assessments. Like a smart assistant or GPS for medical decisions, they can speed diagnosis, reduce errors and lower costs, so investors watch adoption rates, regulatory approval, reimbursement and demonstrated clinical benefit as drivers of market value and risk.

ehr technical

EHR stands for electronic health record, a digital version of a patient’s complete medical file that replaces paper charts and collects diagnoses, medications, test results and treatment history in one place. For investors, EHR systems matter because they drive recurring revenue for software and services, affect healthcare providers’ costs and efficiency, and create data assets and integration opportunities that can influence a company’s growth and regulatory risk.

pd-l1 medical

PD-L1 is a protein found on the surface of some cells that acts like a stop sign for the immune system, telling certain immune cells to back off. It matters to investors because many cancer drugs and diagnostic tests target or measure PD-L1 to unlock immune responses or predict which patients will benefit, affecting clinical success, regulatory approval, and potential sales in the oncology market.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Expanded platform delivers patient insights across six new clinical scenarios in breast, colorectal, ovarian, prostate, and urothelial cancers

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a significant expansion of new indications to its AI-enabled Next platform ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Next establishes a new category of "real-time clinical intelligence" — a departure from legacy retrospective analyses and generic EHR alerts — designed to facilitate the delivery of precision medicine.

To demonstrate the real-world impact of these expanded capabilities, Tempus will showcase a landmark study at ASCO 2026, describing clinically meaningful improvements in rates of biomarker testing for early-stage non-small cell lung cancer (eNSCLC) after the implementation of Tempus Next. The multi-center prospective study evaluated the deployment of the Tempus Next AI-enabled clinical decision support system (AI-CDSS) across 662 eNSCLC patients at six diverse U.S. community health systems.

The Next platform drove significant behavioral change and successfully closed critical care gaps by analyzing unstructured EHR data to identify patients who did not receive guideline-directed biomarker testing. Key findings from the study include:

• The implementation of real-time interventions delivered an absolute testing rate lift of +24% for ALK, +18% for EGFR, and +13% for PD-L1 within 90 days of pathologic diagnosis.
• The program translated testing directly into optimized therapy management, with 89% of treated patients receiving guideline-concordant therapy.

The expanded platform will surface insights from patients across six new clinical scenarios in breast, colorectal, ovarian, prostate, and urothelial cancers. Furthermore, Next has introduced a suite of advanced intelligence capabilities that enable precision medicine teams to map patient experiences and develop targeted care gap programs that support their institution’s health equity initiatives.

“The true challenge in precision oncology is the data fragmentation that hides critical care gaps across the patient journey,” said Ryan Fukushima, CEO of Data and Apps at Tempus. “By expanding Next, we are providing our health systems partners with a 360-degree view to not only identify these gaps but to quantify the truly addressable opportunities for intervention. Our goal is to ensure that clinical innovation reaches every patient, closing the gap between the latest biomarker-driven therapies and community-level care to improve outcomes at scale.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding potential impact of Tempus’ expansion of the Next Platform. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260528392115/en/

Tempus
Hanah Heintzelman
hanah.heintzelman@tempus.com

Source: Tempus AI, Inc.